中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2011年
5期
296-299
,共4页
武鸿美%刘艳辉%林锋%徐方平%罗东兰%张芬%庄恒国%骆新兰%吴伍林%林兴滔
武鴻美%劉豔輝%林鋒%徐方平%囉東蘭%張芬%莊恆國%駱新蘭%吳伍林%林興滔
무홍미%류염휘%림봉%서방평%라동란%장분%장항국%락신란%오오림%림흥도
胃肿瘤%基因,erbB-2%免疫组织化学%预后
胃腫瘤%基因,erbB-2%免疫組織化學%預後
위종류%기인,erbB-2%면역조직화학%예후
Stomach neoplasms%Genes,erbB-2%Immunohistochemistry%Prognosis
目的 评估中国胃癌人群中HEB2蛋白表达的流行病学情况,分析其与患者临床病理学参数之间的关系,探讨HEB2蛋白表达与胃癌患者预后的关系.方法 使用免疫组织化学方法检测胃癌患者中HER2蛋白的表达,以修订后HereepTest评分标准进行评分.x2检验分析HEB2蛋白表达与胃癌患者临床病理学参数之间的关系.生存分析应用Kaplan-Meier法,生存率比较采用Logrank 检验.结果 860例患者中位年龄59岁,男女比例为2.06∶1,其中进展期胃癌患者为774例.使用修订后的HercpTest评分标准评判HER2蛋白阳性表达(3+)的患者为77例(9.0%,77/860),其中进展期胃癌中的HER2阳性表达患者是69例,占进展期胃癌的8.9%(69/774).HEB2蛋白在胃癌中的阳性表达与肿瘤分化、Lauren分型及WHO分型相关,与年龄、性别、肿瘤发生部位及临床分期不相关.生存分析提示HER2蛋白阳性表达的胃癌患者生存率与阴性表达者无明显差异.结论 虽然胃癌HER2蛋白的阳性表达与肿瘤分化及组织学类型相关,但其可能不是胃癌患者的独立预后因子;HER2蛋白在胃癌中的阳性表达可能不影响胃癌患者的预后.
目的 評估中國胃癌人群中HEB2蛋白錶達的流行病學情況,分析其與患者臨床病理學參數之間的關繫,探討HEB2蛋白錶達與胃癌患者預後的關繫.方法 使用免疫組織化學方法檢測胃癌患者中HER2蛋白的錶達,以脩訂後HereepTest評分標準進行評分.x2檢驗分析HEB2蛋白錶達與胃癌患者臨床病理學參數之間的關繫.生存分析應用Kaplan-Meier法,生存率比較採用Logrank 檢驗.結果 860例患者中位年齡59歲,男女比例為2.06∶1,其中進展期胃癌患者為774例.使用脩訂後的HercpTest評分標準評判HER2蛋白暘性錶達(3+)的患者為77例(9.0%,77/860),其中進展期胃癌中的HER2暘性錶達患者是69例,佔進展期胃癌的8.9%(69/774).HEB2蛋白在胃癌中的暘性錶達與腫瘤分化、Lauren分型及WHO分型相關,與年齡、性彆、腫瘤髮生部位及臨床分期不相關.生存分析提示HER2蛋白暘性錶達的胃癌患者生存率與陰性錶達者無明顯差異.結論 雖然胃癌HER2蛋白的暘性錶達與腫瘤分化及組織學類型相關,但其可能不是胃癌患者的獨立預後因子;HER2蛋白在胃癌中的暘性錶達可能不影響胃癌患者的預後.
목적 평고중국위암인군중HEB2단백표체적류행병학정황,분석기여환자림상병이학삼수지간적관계,탐토HEB2단백표체여위암환자예후적관계.방법 사용면역조직화학방법검측위암환자중HER2단백적표체,이수정후HereepTest평분표준진행평분.x2검험분석HEB2단백표체여위암환자림상병이학삼수지간적관계.생존분석응용Kaplan-Meier법,생존솔비교채용Logrank 검험.결과 860례환자중위년령59세,남녀비례위2.06∶1,기중진전기위암환자위774례.사용수정후적HercpTest평분표준평판HER2단백양성표체(3+)적환자위77례(9.0%,77/860),기중진전기위암중적HER2양성표체환자시69례,점진전기위암적8.9%(69/774).HEB2단백재위암중적양성표체여종류분화、Lauren분형급WHO분형상관,여년령、성별、종류발생부위급림상분기불상관.생존분석제시HER2단백양성표체적위암환자생존솔여음성표체자무명현차이.결론 수연위암HER2단백적양성표체여종류분화급조직학류형상관,단기가능불시위암환자적독립예후인자;HER2단백재위암중적양성표체가능불영향위암환자적예후.
Objective To evaluate the epidemiological status of HER2 protein expression in Chinese patients with gastric carcinoma,and to study its clinical and prognostic significance and the association with the clinicopathological features.Methods The clinical data were reviewed in 860 patients with gastric carcinoma admitted to Guangdong General Hospital from 2003 to 2010.The HER2 status Was evaluated using immunohistochemistry(IHC).The modified Heroep Test scoring criterion Was used to assess HER2 protein expression.The association between HER2 expression and clinicopathological features was analyzed by X2 test.Kaplan-Meier analysis,log-rank test and Cox regression model were used for the survival analysis.Results The median age of the patients Was 59 years, and the male-to-female ratio was 2.06∶1.Positive expression of HER2 protein(3+)was found in 77(9.0%)cases of gastric carcinoma,and in 69(8.9%)edvanced gastric cancers.There waS significantly positive association between HER2 overexpression and tumor differentiation, Lanren claasification and WHO classification.No significant association Was observed between HER2 protein expression and patients'age,gender,tumor location and clinical stage.There waS no statistically significant difference in survival rate between patients with positive HER2expression and negative ones. Conclusion Though there WaS significantly positive association between HER2 expression status and tumor differentiation,histological type,it may be of limited prognostic value in gastric cancer patients.
